Show Cart
PipelineReview.com
Home
My cart / Checkout
Contact Us
Home
News Channels
Antibodies
DNA, RNA & Cells
Protein & Peptides
Small Molecules
Vaccines
More News
Reports
All Products
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells & NK Cells
Immuno-Oncology
mRNA Vaccines & Therapeutics
Pipeline Database
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Proteins & Peptides
Vaccines
FREE reports
Offers
Press Room
About Us
Home
News Channels
Antibodies
DNA, RNA & Cells
Protein & Peptides
Small Molecules
Vaccines
More News
Reports
All Products
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells & NK Cells
Immuno-Oncology
mRNA Vaccines & Therapeutics
Pipeline Database
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Proteins & Peptides
Vaccines
FREE reports
Offers
Press Room
About Us
Home
News Channels
News Channels
06 Feb 2019
BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
06 Feb 2019
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
06 Feb 2019
Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109
06 Feb 2019
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor
06 Feb 2019
MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
05 Feb 2019
Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan
05 Feb 2019
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
05 Feb 2019
FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam)
05 Feb 2019
Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers
05 Feb 2019
US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897
05 Feb 2019
Genentech Submits Supplemental Biologics License Application to FDA for Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
05 Feb 2019
Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
05 Feb 2019
CHMP recommends EU approval of Roche's Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
05 Feb 2019
Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388
05 Feb 2019
ProteoNic Biotechnology Licenses Protein Production Technology to Eli Lilly and Company
04 Feb 2019
Chugai’s Hemlibra® Gains Positive CHMP Opinion in Severe Hemophilia A Without Inhibitors
04 Feb 2019
Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral Anticoagulant
04 Feb 2019
SK life science announces FDA acceptance of NDA submission for cenobamate, an investigational antiepileptic drug
04 Feb 2019
Neurana Pharmaceuticals Announces First Patient Enrolled in the "STAR Study," a Phase 2 Dose Ranging Study of Tolperisone in Acute Muscle Spasms of the Back
04 Feb 2019
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Page 5 of 2228
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Currencies
Australian dollar $
British pound £
Canadian dollar $
Danish krone kr
Euro €
Japanese yen ¥
Swedish krona kr
Swiss franc CHF
United States dollar $
Shopping cart
Cart empty
Please wait
Latest report
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018
Featured Products
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends
Latest Target Pipeline
Interleukin-33/Receptor Targeted Antibodies – Target Pipeline List 12/2018
Currencies
Australian dollar $
British pound £
Canadian dollar $
Danish krone kr
Euro €
Japanese yen ¥
Swedish krona kr
Swiss franc CHF
United States dollar $
Shopping cart
Cart empty
Please wait
Latest report
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018
Featured Products
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends
Latest Target Pipeline
Interleukin-33/Receptor Targeted Antibodies – Target Pipeline List 12/2018
La Merie Biologics
FREE Weekly News Bulletin
Sign Up
2017 Sales of
Antibodies & Proteins
Get it now
New Product Alert
For La Merie Publishing
Sign Up
Top